Bridgefront Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$998K Sell
6,698
-8,750
-57% -$1.23M 0.24% 138
2026
Q2
$1.95M Buy
+15,448
New +$2.04M 0.51% 33
2025
Q3
– Sell
-3,924
Closed -$435K – 672
2025
Q2
$435K Buy
+3,924
New +$418K 0.12% 308
2024
Q2
– Sell
-9,424
Closed -$690K – 552
2024
Q1
$690K Buy
+9,424
New +$725K 0.52% 32
2023
Q3
– Sell
-5,890
Closed -$454K – 471
2023
Q2
$454K Buy
+5,890
New +$470K 0.25% 136
2022
Q3
– Sell
-3,564
Closed -$220K – 372
2022
Q2
$220K Buy
+3,564
New +$221K 0.24% 207
2021
Q3
– Sell
-4,039
Closed -$278K – 472
2021
Q2
$278K Buy
+4,039
New +$270K 0.1% 376

Other funds holding GILD

Bridgefront Capital's GILD Position: Q3 2026 in Review

Bridgefront Capital reduced its Gilead Sciences (GILD) stake by 57% in Q3 2026, selling an estimated $1.23M and leaving 6,698 shares worth $998K. The position accounts for 0.24% of the portfolio, ranked #138.

Bridgefront Capital first reported a position in GILD in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.95M in Q2 2026. 2,357 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Bridgefront Capital held 6,698 shares of Gilead Sciences worth $998K as of Q3 2026.
  • Bridgefront Capital sold 8,750 Gilead Sciences shares in Q3 2026, an estimated $1.23M.
  • Gilead Sciences made up 0.24% of Bridgefront Capital's portfolio in Q3 2026, its #138 holding.
  • Bridgefront Capital first reported a position in Gilead Sciences in Q2 2021 and has held it in 7 quarters since.
  • Bridgefront Capital's Gilead Sciences position peaked at $1.95M in Q2 2026.
  • 2,357 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Bridgefront Capital's 13F filing for Q3 2026, filed 16 Nov 2026.